KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy



Status:Recruiting
Conditions:Lung Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:7/16/2013
Start Date:November 2011

Use our guide to learn which trials are right for you!

A Multi-Center, Phase 3, Double-Blind, Randomized, and Controlled Trial of KD019 vs Erlotinib in Subjects With Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Progressed After First- or Second-Line Chemotherapy


This study involves treatment with KD019 or erlotinib in patients with Non-small cell lung
cancer (NSCLC) who have progressed after first- or second- line chemotherapy. It is
hypothesized that KD019 can prolong survival compared with erlotinib.


For Eligibility subjects must have:

- failed one or two previous courses of therapy.

- have no active brain metastasis. Treated non-active brain metastasis are acceptable.

- cannot have received an EGFR inhibitor (Tarceva[erlotinib] or Iressa[gefitinib]) in
the past.

- has demonstrated progressive disease.
We found this trial at
2
sites
333 Cedar Street
New Haven, Connecticut 06520
(203) 785-4095
Yale Cancer Center Yale Cancer Center combines a tradition of innovative cancer treatment and quality...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
Farmington, New Mexico 87401
?
mi
from
Farmington, NM
Click here to add this to my saved trials